Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
HOME > REGULATORY
REGULATORY
- PFSB to Monitor Drug Companies’ Promotional Activities at 20 Selected Medical Facilities
August 28, 2015
- PFSB to Request Budget of 10.7 Billion Yen in FY2016 to Improve Environments for Development of Innovative Drugs, Quality of Generics
August 28, 2015
- Health Service Bureau Seeks 469.1 Billion Yen in FY2016 Budget, 120.2 Billion Yen for Intractable Diseases
August 28, 2015
- Health Policy Bureau Seeks 193.6 Billion Yen in FY2016 Budget, 6.6 Billion Yen for Clinical Research Promotion
August 28, 2015
- FPMAJ Wants Continuation of Innovation Premium, No Market Price-Based Price Revision in 2017: Chuikyo Hearings
August 27, 2015
- Chuikyo’s HTA Panel Issues Interim Report, Appraisal Results to Be Used to Re-Price Selected Listed Drugs
August 27, 2015
- Development Projects, Regulatory Filings Increasing Thanks to Innovation Premium: PhRMA, EFPIA
August 27, 2015
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- Chuikyo Reps Trade Barbs over Pricing of Harvoni, Listing OK'ed by a Whisker
August 27, 2015
- Chuikyo OKs Listing of Harvoni, Peak Sales Put at 119 Billion Yen in 2nd Year
August 26, 2015
- 4 Pharma Groups Welcome MHLW’s “Comprehensive Strategy”
August 25, 2015
- MHLW OKs New Indications for Remicade, Other Products
August 25, 2015
- MHLW Reveals Outline of “Comprehensive Strategy” for Pharma Sector
August 25, 2015
- Drug Pricing Tomorrow: MHLW Councilor Takeda Says NHI Drug Prices Should Mirror Evaluation of Individual Firms
August 24, 2015
- Editor’s Pick: Five Healthcare News Headlines for August 10 - August 23
August 24, 2015
- PMDA Reviewing Opdivo for Risk of Myasthenia Gravis
August 24, 2015
- Novartis’s Equa-Metformin Combination Drug Added to PAFSC 1st Committee’s Review List for Aug. 28
August 24, 2015
- MHLW Designates Carfilzomib as Orphan Drug
August 21, 2015
- Lawmakers Discuss Cost-Effectiveness of Measures to Prevent Cervical Cancer
August 21, 2015
- Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
August 21, 2015
ページ
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…